Titre :

Allogeneic HCT for adults with B-cell precursor acute lymphoblastic leukemia harboring IKZF1 gene mutations. A study by the Acute Leukemia Working Party of the EBMT

Auteur(s) :

Giebel, Sebastian [Auteur]
Labopin, Myriam [Auteur]
CEREST-TC [CHU Saint-Antoine]
Socie, Gerard [Auteur]
Beauvais, David [Auteur]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Klein, Stefan [Auteur]
Wagner-Drouet, Eva-Maria [Auteur]
Blaise, Didier [Auteur]
Institut Paoli-Calmettes [IPC]
Nguyen-Quoc, Stephanie [Auteur]
CHU Pitié-Salpêtrière [AP-HP]
Bourhis, Jean-Henri [Auteur]
Institut Gustave Roussy [IGR]
Thiebaut, Anne [Auteur]
Centre Hospitalier Universitaire [CHU Grenoble] [CHUGA]
Labussiere-Wallet, Hélène [Auteur]
Service d’Hématologie [Centre Hospitalier Lyon Sud - HCL]
Charbonnier, Amandine [Auteur]
Laboratoire d'Hématologie [CHU Amiens]
Berceanu, Ana [Auteur]
Service d'Hématologie [CHRU Besançon]
Diez-Martin, José Luis [Auteur]
Fegueux, Nathalie [Auteur]
Université de Montpellier [UM]
Esteve, Jordi [Auteur]
Nagler, Arnon [Auteur]
Mohty, Mohamad [Auteur]
Centre de Recherche Saint-Antoine [CRSA]

Titre de la revue :

Bone Marrow Transplantation

Nom court de la revue :

Bone Marrow Transplant.

Numéro :

56

Pagination :

1047–1055

Date de publication :

2022-03-28

ISSN :

0268-3369

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

The presence of IKZF1 gene mutations is associated with poor prognosis of B-cell precursor acute lymphoblastic leukemia (BCP-ALL). The goal of this retrospective study was to evaluate outcome of allogeneic hematopoietic ...
Lire la suite >The presence of IKZF1 gene mutations is associated with poor prognosis of B-cell precursor acute lymphoblastic leukemia (BCP-ALL). The goal of this retrospective study was to evaluate outcome of allogeneic hematopoietic cell transplantation (allo-HCT) in this population. Ninety-five patients transplanted in first (n = 75) or second (n = 20) complete remission (CR) from either HLA-matched sibling (n = 32), unrelated (n = 47) or haploidentical (n = 16) donor were included in the analysis. The probabilities of the overall survival (OS) and leukemia-free survival (LFS) at 2 years were 55% and 47%, respectively. Relapse incidence (RI) was 32% while non-relapse mortality (NRM), 21%. The incidence of grade II–IV acute graft-versus-host disease (GVHD) and chronic GVHD was 34% and 30%, respectively. The probability of GVHD and relapse-free survival (GRFS) was 35%. In a multivariate analysis positive minimal residual disease (MRD) status was associated with decreased chance of LFS (HR = 3.15, p = 0.004) and OS (HR = 2.37, p = 0.049) as well as increased risk of relapse (HR = 5.87, p = 0.003). Disease stage (CR2 vs. CR1) affected all, LFS, OS, GRFS, RI, and NRM. Results of allo-HCT for patients with BCP-ALL and IKZF1 mutations are generally improving, however, individuals with detectable MRD have poor prognosis and require additional intervention prior to transplantation.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

Université de Lille
Inserm
CHU Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Date de dépôt :

2024-01-12T08:55:37Z
2024-01-30T09:04:01Z